NKGen Biotech to present long-term troculeucel data from single Alzheimer’s patient at CTAD 2026
NKGN•NKGen Biotech will present findings from a single-patient analysis of long-term troculeucel treatment in moderate Alzheimer’s disease at CTAD in Boston on Nov. 16–19, 2026.
1. Presentation details
The analysis examines cognitive outcomes after Phase 1 treatment and an additional 12 months in an open-label extension. The poster presentation is scheduled for Nov. 16–17.
